Radiotherapy (RT), besides cancer cells, also affects the tumor microenvironment (TME):
tumor blood vessels and cells of the immune system. It damages endothelial cells and …

The immunogenicity of cancer cells is an emerging determinant of anti‐cancer
immunotherapy. Beyond develo** immunostimulatory regimens like dendritic cell‐based …

Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-
associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor …

Molecular and cellular effects of radiotherapy on tumor microenvironment (TME) can help
prime and propagate antitumor immunity. We hypothesized that delivering radiation to all …

The term 'immunogenic cell death'(ICD) denotes an immunologically unique type of
regulated cell death that enables, rather than suppresses, T cell-driven immune responses …

Immunotherapy, where the patient's own immune system is exploited to eliminate tumor
cells, has become one of the most prominent new cancer treatment options in the last …

The expression “immunogenic cell death”(ICD) refers to a functionally unique form of cell
death that facilitates (instead of suppressing) a T cell-dependent immune response specific …

Radiotherapy (RT) is still one of the standard cancer therapies, with up to two third of all
cancer patients with solid tumors being irradiated in the course of their disease. The aim of …

Immune checkpoint blockade (ICB) has revolutionised the treatment of solid tumours, yet
most patients do not derive a clinical benefit. Resistance to ICB is often contingent on the …

In situ tumor vaccination is preliminarily pursued to strengthen antitumor immune response.
Immunogenic tumor cell death spontaneously releases abundant antigens and adjuvants for …